BiPER Therapeutics has now secured €800k in bridge funding to help develop its novel BiP inhibitor, BPR001-615, for the treatment of gastrointestinal malignancies. The funding raised will assist in refining BPR001-615’s pathology and regulatory preclinical study and advance toward first-in-human trials.